Navigation Links
First Clinical Experience With Soliris(R) in Treating Patients With Two Rare Complement-Mediated Diseases Presented at ASH Annual Meeting
Date:12/7/2008

es in early stages of development. This press release and further information about Alexion Pharmaceuticals, Inc. can be found at www.alexionpharm.com.


    [ALXN-G]

Safe Harbor Statement

This news release contains forward-looking statements, including statements related to potential health and medical benefits from Soliris. Forward-looking statements are subject to factors that may cause Alexion's results and plans to differ from those expected, including for example, decisions of regulatory authorities regarding marketing approval or material limitations on the marketing of Soliris, delays in arranging satisfactory manufacturing capability and establishing commercial infrastructure, delays in developing or adverse changes in commercial relationships, the possibility that results of clinical trials are not predictive of safety and efficacy results of Soliris in broader patient populations, the possibility that initial results of commercialization are not predictive of future rates of adoption of Soliris, the risk that third parties won't agree to license any necessary intellectual property to Alexion on reasonable terms or at all, the risk that third party payors will not reimburse for the use of Soliris at acceptable rates or at all, the risk that estimates regarding the number of PNH patients are inaccurate, the risk that pending litigation may be resolved adversely, and a variety of other risks set forth from time to time in Alexion's filings with the Securities and Exchange Commission, including but not limited to the risks discussed in Alexion's Quarterly Report on Form 10-Q for the period ended September 30, 2008, and in Alexion's other filings with the Securities and Exchange Commission. Alexion does not intend to update any of these forward-looking statements to reflect events or circumstances after the date hereof, except when a
'/>"/>

SOURCE Alexion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. CVBT Doses First Patient in its Phase II Clinical Trial for Severe Coronary Heart Disease
2. FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder
3. Celator(R) Pharmaceuticals Announces Enrollment of First Patient in Phase 2 Study with CPX-351
4. Alba Therapeutics Announces Enrollment of Its First European Patient in Global Phase IIb Study of Larazotide Acetate for Treatment of Active Celiac Disease
5. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
6. Diagenic Announces Launch of First Breast Cancer Gene-Expression Blood Test
7. Zevalin(R) Following Short-Course Chemotherapy with CHOP + Rituximab (CHOP-R) Doubles Complete Remission Rate in First-Line Treatment of Follicular Non- Hodgkins Lymphoma
8. Celladon Announces Presentation of Clinical Data From First-in-Human MYDICAR(R) Trial for Advanced Heart Failure at American Heart Association Scientific Sessions
9. Sequoia Pharmaceuticals Presents In Vitro and First-in-Human Data Supporting Further Development of SPI-256, a Novel Investigational Protease Inhibitor
10. ULURU Inc. Announces the Commencement of First Clinical Study Using Altrazeal(TM) Silver
11. First Town Hall Meeting on Inequities in Clinical Trials to Take Place at the Harlem Hospital Center on October 20
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... 2015 Research and Markets ... "Investigation Report on China,s Ranibizumab Market, 2012-2019" ... ranibizumab was approved by CFDA to treat wet age- ... a product of Novartis, is available in the Chinese ... developed drug for the treatment of wet AMD in ...
(Date:8/28/2015)... , Aug. 28, 2015  Perrigo Company plc ("Perrigo") ... has completed the acquisition of leading OTC brands from ... million. The transaction is a clear demonstration of Perrigo,s ... leading European distribution network spanning 36 countries.  ... Papa commented, "We are excited to complete this ...
(Date:8/28/2015)... 2015 The report "Eubiotics Market by Type (Probiotics, ... and Aquaculture), & by Region ( North America ... , and Rest of the World) - Global Trends and ... Eubiotics was valued at USD 4.62 Billion in 2014 and ... a CAGR of 7.4% from 2015 to 2020. ...
Breaking Medicine Technology:Investigation Report on China's Ranibizumab Market, 2012-2019 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 3Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 4Eubiotics Market Worth 7.05 Billion USD by 2020 2Eubiotics Market Worth 7.05 Billion USD by 2020 3Eubiotics Market Worth 7.05 Billion USD by 2020 4Eubiotics Market Worth 7.05 Billion USD by 2020 5
... brings hope for the fight against prostate cancer. While the ... receive this unfortunate diagnosis in 2012, numbers also indicate that ... deaths dropped 39 percent since the 1990s. The widespread adaptation ... the form of robotic prostatectomy , is leading the ...
... patent cliffs and shrinking pipelines, the pharmaceutical industry is ... M&A activities - as a way to maintain growth ... one to effectively put into practice. The process of ... potential pitfalls. With 2012 shaping up to be a ...
Cached Medicine Technology:PSA Testing and Robotic Surgery Take on Prostate Cancer 2PSA Testing and Robotic Surgery Take on Prostate Cancer 3Excellence Services Program Delivers a Road Map to Successfully Guide the Pharmaceutical Industry Through the New Alliance Landscape 2
(Date:8/29/2015)... ... ... Brands like Toppik , Eau Thermale Avene and Bliss are now available on ... was required to qualify for free standard shipping,” said Jennifer Ramirez, the public relations ... of the item’s selling price.” , With competitive pricing in the e-commerce market for ...
(Date:8/29/2015)... ... 29, 2015 , ... ProDrop Particles includes over 40 particle backdrops designed for ... unique footage that users can shrink and stretch in the Final Cut Pro X ... customize color, brightness, scale, speed, range, and flare attributes with intuitive controls found in ...
(Date:8/29/2015)... ... August 29, 2015 , ... Hamstring strain ... with stretching, soft tissue manipulation. Platelet rich plasma injections also have mixed ... to improve treatment outcomes. This localized treatment seems to address the symptoms ...
(Date:8/29/2015)... ... August 29, 2015 , ... Vascular Health Sciences announced ... Arterosil and Arterosil HP, and that all claims and counterclaims have been irrevocably ... LLC (VHS) in the United States District Court for the Southern District of ...
(Date:8/28/2015)... Madre, CA (PRWEB) , ... August 28, 2015 ... ... solutions to wound center management, Decatur County Memorial Hospital recently transitioned management companies ... model of Wound Center Management for their outpatient wound center. , Transitioning ...
Breaking Medicine News(10 mins):Health News:TheBeautyPlace.com Discounts Shipping on Select Brands 2Health News:FCPX Effects Developer, Pixel Film Studios, Releases ProDrop Particles. 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 3Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 2Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 3Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 4
... LAKE FOREST, Ill., July 29 Akorn, Inc. (Nasdaq: AKRX ) will ... will host a conference call on Tuesday, August 11 to discuss quarterly results followed by ... Akorn Second ... Tuesday, August 11, 2009 at 10:00 a.m. Eastern Time, ...
... , KALAMAZOO, Mich., July 29 Stryker ... of its Board of Directors to nine and the election of Dr. ... Datar serves as Senior Associate Dean and Director of Research at the ... Arthur Lowes Dickinson Professorship at Harvard University since joining that organization in ...
... Alzheimer,s prevention efforts, researcher says, , WEDNESDAY, July 29 ... play a role in disrupting the memory formation process ... impairment of Alzheimer,s disease, a new study contends. , ... which damage neurons and are characteristic of Alzheimer,s disease, ...
... , SANTA ROSA, Calif., July 29 ... halter worn by champion racehorse Rachel Alexandra prior to her historic victory ... race since 1924. The winning bid--$2,859.99--will be donated by the horse,s owners, ... , , Today, the second item in the five-item ...
... ... Health Ventures (CHV) makes leading medical transcription service, MxSecure, available to 7,000 member health ... ... and MxSecure, Inc. today announced an agreement that names MxSecure a preferred partner for ...
... , , , ... nonprofit organization established by Cristie Kerr in 2003 with a mission ... fifth annual charity golf classic will be held at Liberty National. ... of golf followed by a dinner reception and poker tournament. ...
Cached Medicine News:Health News:Akorn, Inc. Announces Second Quarter 2009 Earnings Release and Conference Call Information 2Health News:Stryker Announces Election of New Director 2Health News:Protein Clumps May Appear Years Before Memory Problems 2Health News:Ohio Man Top Bidder for Preakness Winner's Halter, First of Five Items in Horse's Season-Long Auction Series 2Health News:Medical Transcription Service, MxSecure, Partners with CHV to Enhance Community Health Care 2Health News:Medical Transcription Service, MxSecure, Partners with CHV to Enhance Community Health Care 3Health News:Birdies for Breast Cancer Announces Fifth Annual Charity Golf Classic Hosted by Top Women's Golfer, Cristie Kerr 2
... 50/60 Hz, 100/120 V Fast - Powerful ... rotor spins up to 14,000 rpm (18,000 x g) ... Cell Virus Isolation Fits on crowded ... Comes complete with a 24-place aerosol-tight, autoclavable fixed-angle rotor ...
Inquire...
... designed to create the ideal environment for nucleic ... 99.9C) , Variable speed control (10 to ... it be for washing or hybridizing , ... inside the chamber, ,is situated above a touch ...
... HybriCycler Hybridization Oven with circular clear acrylic ... tubes. HC-3000 HybriCycler Oven features microprocessor operation ... feet balance the unit., Carousel rotates ... carousel is ,easily removable , Bottle ...
Medicine Products: